William Blair Starts LogicBio Therapeutics (LOGC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
November 13, 2018 6:47 AM ESTChardan Capital Markets analyst Gbola Amusa initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Buy rating and a price target of $20.00.
The analyst comments "LogicBios pipeline reflects a focus on indications that play to its strengths. The advantage lies in indications where 1)... More
Barclays Starts LogicBio Therapeutics (LOGC) at Overweight
November 13, 2018 4:16 AM ESTBarclays analyst Gena Wang initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on LogicBio Therapeutics click here. For more ratings news on LogicBio Therapeutics click here.
Shares of LogicBio Therapeutics closed at $13.72 yesterday.
... More


